The Revolution Medicines trial of daraxonrasib, a RAS(ON) inhibitor, delivered median overall survival nearly twice that of chemotherapy in advanced pancreatic ductal adenocarcinoma, marking the first such result in this disease. Published simultaneously in the New England Journal of Medicine and presented at ASCO 2026 plenary, the study represents a randomized controlled trial (RCT) sponsored by the manufacturer, though exact sample size, KRAS mutation enrichment details, and independent data monitoring committee oversight remain sparsely reported in initial coverage. This builds on prior observational data from smaller RAS-targeted cohorts (e.g., sotorasib studies in NSCLC) but contrasts with failed phase 3 efforts like those for PEGPH20. What STAT overlooked is the likely heavy selection for KRAS G12D/V/C mutations—present in ~90% of pancreatic cancers—raising questions about generalizability versus the broader population. Conflicts of interest are evident: Revolution Medicines funded the work, with authors disclosing equity ties. Synthesizing with ASCO abstract patterns and NEJM peer review standards, this RCT (high-quality design) offers practice-changing potential in a field starved for options, yet real-world durability and resistance mechanisms require phase 4 confirmation. Earlier hype around similar agents (e.g., 2019-2023 KRAS trials) showed initial promise followed by modest gains once larger cohorts emerged.